BRAF and melanoma: While therapeutic targeting of RAF and MEK via small molecule inhibitors has been clinically approved for V600E/K-mutated BRAF melanoma, the clinical application of these inhibitors in BRAF mutant NSCLC is at its early stages and requires further preclinical and clinical investigations [7, 8].